Changes are happening - please bear with us while we update our site.

Changes are happening - please bear with us while we update our site. Click here to give us your advice and feedback.

Mayne Pharma (ASX:MYX) share price springs up and down

The Mayne Pharma Group Ltd (ASX: MYX) share price soared by 17% last Friday but has dropped slightly today. What's happening with Mayne Pharma share price?

The Mayne Pharma Group Ltd (ASX: MYX) share price soared by 17% last Friday but has dropped slightly today. What is happening with Mayne Pharma share price?

Mayne Pharma develops, manufactures and markets branded and generic pharmaceutical products globally.

MYX share price

Source: Rask Media MYX 6-months share price chart

Mayne Pharma gains FDA approval on a new drug

The meteoric rise in the Maybe Pharma share price is due to the US Food and Drug Administration (FDA) approval of its new oral contraceptive, Nextstellis.

Mayne Pharma estimates the commercial launch of this new product to occur by the end of June 2021.

Nextstellis was developed by Mirtha Pharmaceuticals and is the only contraceptive pill containing estetrol, a native estrogen, now produced from a plant source.

The company advises estetrol is the first new estrogen introduced in the US in more than 50 years.

According to one professor at the University of California, it provides fewer side effects for patients compared to alternative options.

Mayne Pharma has paid US$11 million in cash as well as 85.8 million in shares to Mirtha for receiving this FDA approval.

My thoughts

As part of the Rask Investment Philosophy, I focus on companies that are within my circle of competence.

Given my limited knowledge about the pharmaceutical market, I tend to stay well away from biotech companies.

Whilst there have been big success stories in this space like CSL Limited (ASX: CSL), it is difficult to identify data points to monitor because financial performance is mainly driven by successful experiments.

I would rather monitor these 2 ASX growth shares covered in my article.

I’d also suggest getting a free Rask account to access our full stock reports.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, the author of this article does not have a financial or commercial interest in any of the companies mentioned.
Skip to content